Upload
nguyendat
View
213
Download
0
Embed Size (px)
Citation preview
WELCOME LETTER FACULTY
on New Drugs (and New Concepts) 5 International Meetingth
in Breast Cancer
ROME, NOVEMBER 9-10, 2017Regina Elena National Cancer InstituteBastianelli Congress Centre
PRESIDENT: Francesco Cognetti
V. Adamo, Messina (Italy)
G. Arpino, Naples (Italy)
A. Bardia, Boston (USA)
G. Bianchini, Bergamo (Italy)
C. Boni, Reggio Emilia (Italy)
C. Botti, Rome (Italy)
E. Bria, Verona (Italy)
P. Bruzzi, Genoa (Italy)
R.T. Chlebowski, Los Angeles (USA)
S. Cinieri, Brindisi (Italy)
F. Cognetti, Rome (Italy)
P. Conte, Padua (Italy)
M. Cristofanilli, Chicago (USA)
J. Crown, Dublin (Ireland)
G. Curigliano, Milan (Italy)
R. Danesi, Pisa (Italy)
A. De Censi, Genoa (Italy)
M. De Laurentiis, Naples (Italy)
S. De Placido, Naples (Italy)
L. Del Mastro, Genoa (Italy)
A. Di Leo, Prato (Italy)
M.J. Duffy, Dublin (Ireland)
A. Fabi, Rome (Italy)
G. Ferretti, Rome (Italy)
R.S. Finn, Los Angeles (USA)
C. Fontanella, Aviano (Italy)
A. Gennari, Genoa (Italy)
P. Giacomini, Rome (Italy)
S. Gori, Negrar-VR (Italy)
V. Guarneri, Padua (Italy)
A. Howell, Manchester (United Kingdom)
M. Lambertini, Genoa (Italy)
C.L. Loprinzi, Rochester (USA)
V. Lorusso, Bari (Italy)
R. Masetti, Rome (Italy)
D.C. McKenzie, Vancouver (Canada)
G. Mustacchi, Trieste (Italy)
G. Naso, Rome (Italy)
C. Nisticò, Rome (Italy)
E. Perez, San Francisco (USA)
P. Pronzato, Genoa (Italy)
F. Puglisi, Udine (Italy)
L.M. Repetto, Rome (Italy)
F. Roila, Perugia (Italy)
V. Sacchini, Milan (Italy)
D. Santini, Rome (Italy)
F. Scaldaferri, Rome (Italy)
M. Scaltriti, New York (USA)
D.B. Solit, New York (USA)
U. Tirelli, Aviano (Italy)
C. Tondini, Bergamo (Italy)
C.J. Twelves, Leeds (United Kingdom)
S. Vella, Rome (Italy)
K. Willard-Gallo, Brussels (Belgium)
WITH AN UNRESTRICTED EDUCATIONAL GRANT OF
PRINCIPAL SPONSORS
MAJOR SPONSORS
SPONSORS
Dear Friends and Colleagues,
it is with pleasure that I welcome you to Rome for the 5th International Meeting on New Drugs (and New Concepts) in Breast Cancer, bringing together clinicians, mainly medical oncologists, and researchers including this year a substantial translational research component. The issues enlisted in this preliminary program, in particular including data from clinical trials stemming from that original basic research, demonstrate how the translation of basic research into practical clinical tools is particularly active in this disease.
The program has been designed in the pursuit of excellence and, as usually, all lectures will be presented by an international distinguished outstanding faculty who will report all their experiences and developments.
I look forward to joining you and I also hope you can enjoy a unique and pleasant stay in our wonderful City. Francesco Cognetti
AIM Education - Provider n. 93Via G. Ripamonti, 129 - 20141 Milan, ItalyPh. +39 02 56601.1 - Fax +39 02 [email protected] - www.aimeducation.it
AIM Group International
Rome OfficeVia Flaminia, 1068 - 00189 RomePh. +39 06 33053.1 - Fax +39 06 [email protected]://web.aimgroupinternational.com/2017/breastcancer
CME PROVIDER ORGANIZING SECRETARIAT
Under the patronage of
CONGRESS VENUE AND GENERAL INFORMATION
Meeting VenueRegina Elena National Cancer Institute – Raffaele Bastianelli Congress CentreVia Fermo Ognibene, 23 – 00144 Rome
LanguageThe official language of the Congress is English. Simultaneous translation will not be provided.
Certicate of attendanceCertificates will be issued to all registered participants who will expressly make request at the Secretariat Desk at the end of the Congress.
ECM - Educazione Continua in medicina - for Italian delegates onlyL’evento è stato accreditato presso la Commissione Nazionale per la Formazione Continua con Obiettivo Formativo di Processo: integrazione interprofessionale e multiprofessionale, interistituzionale (8) per la Figura Professionale FARMACISTA con specializzazione nelle seguenti discipline FARMACIA OSPEDALIERA; FARMACIA TERRITORIALE; per la Figura Professionale BIOLOGO con specializzazione nelle seguenti discipline BIOLOGO; per la Figura Professionale MEDICO CHIRURGO con specializzazione nelle seguenti discipline ONCOLOGIA; RADIOTERAPIA; CHIRURGIA GENERALE; CHIRURGIA PLASTICA E RICOSTRUTTIVA; ANATOMIA PATOLOGICA; RADIODIAGNOSTICA; MEDICINA GENERALE (MEDICI DI FAMIGLIA); per un numero massimo di n. 200 partecipanti. Oltre tale numero e per professioni/discipline differenti da quelle accreditate non sarà possibile rilasciare i crediti formativi. Si precisa che i crediti verranno erogati a fronte di una partecipazione del 90% ai lavori scientifici e del superamento della prova di apprendimento con almeno il 75% delle risposte corrette. L’EVENTO HA OTTENUTO NR. 8,4 CREDITI FORMATIVI – ID ECM: 93-204540 - ED.1
LOCAL SCIENTIFIC COORDINATOR
Alessandra Fabi
LOCAL SCIENTIFIC COMMITTEE
Daniele AlesiniSimona GasparroPaola Malaguti
SCIENTIFIC COMMITTEE
P. Conte (Padua, I)M. De Laurentiis (Naples, I)S. De Placido (Naples, I)L. Del Mastro (Genoa, I)A. Di Leo (Prato, I)S. Gori (Negrar-VR, I)P. Pronzato (Genoa, I)
• Registration Fee € 183,00 (VAT 22% included) • Registration for doctors of Regina Elena National Cancer Institute FREE • Post graduate students FREE
The registration fee entitles delegates to the following: • entry to scientific sessions • 1 coffee break and 1 buffet lunch on November 9 and 10, 2017 • CME credits • congress material • certificate of attendance
REGISTRATION INFORMATION
09.00 Lecture The tumor microenvironment in breast cancer growth and progression (A. Howell)
1ST SESSION
HER2 POSITIVE TUMORS Chairmen: F. Puglisi, C. Tondini
09.20 New biology concepts (G. Curigliano)09.40 Optimizing neoadjuvant and adjuvant treatment (G. Curigliano) 10.00 When do you add an endocrine drug to the Her2 dual blockade? (G. Arpino)10.20 Treatment duration of HER2-directed agents in metastatic disease (E. Perez) 10.40 Drug resistance: mechanism and clinical results (M. Scaltriti) 11.00 The use of biosimilars (R. Danesi)
11.20 Coffee Break
2ND SESSION
LUMINAL TUMORSChairmen: C. Botti, S. Gori
11.30 The intestinal microbiome (F. Scaldaferri)11.50 CD4/6 inhibitors: the role in the adjuvant/neoadjuvant setting (M. Cristofanilli)12.10 New PI3K inhibitors (G. Curigliano)
3RD SESSION
TRIPLE NEGATIVEChairmen: G. Mustacchi, G. Naso
12.30 Lecture Insights into the biology: new molecular classification for identifying immuno therapeutics targets (K. Willard - Gallo)12.50 New Developments in the Treatment of advanced diseases and biomarkers evidence (M.J. Duffy) 13.10 Neo/adjuvant systemic therapy today (M. Cristofanilli)
13.30 Lunch
4TH SESSION
BRCA AND NEW OPINIONS Chairmen: S. Cinieri, L. Del Mastro
Presenting: R. Masetti 14.00 Surgical update in patients with early disease and BRCA mutation (V. Sacchini)14.20 Novel drugs and new trials in BRCA mutated patients (J. Crown)14.40 Fertility and BRCA mutation (M. Lambertini)
5TH SESSION
IMMUNOSYSTEM AND IMMUNOTHERAPYChairmen: E. Bria, S. De Placido
15.00 Lecture Immunotherapy: what we still need to know? (E. Perez) 15.20 New immunotargets in breast cancer (G. Bianchini)15.40 The combination with nanoparticle molecules (M. De Laurentiis)
16.00 Discussion
6TH SESSION
NEW CONCEPTSChairmen: C. Boni, E. Bria
16.10 From phase I-III to new clinical trials methodologies in breast cancer (P. Bruzzi) 16.30 Trials on druggable mutations, regulatory implications (S. Vella)
Presenting: P. Giacomini 16.50 Lecture Precision medicine in breast cancer today (D.B. Solit)
17.10 Discussion
Presenting: F. Cognetti Lecture09.00 Breast cancer chemo-prevention (A. De Censi)
7TH SESSION
SUPPORTIVE CARE AND LIFESTYLE Chairmen: V. Adamo, C. Nisticò, F. Roila
09.20 Toxicity induced by therapy: the new profile of the oncologist (D. Santini)
THURSDAY, NOVEMBER 9
FRIDAY, NOVEMBER 10
09.40 Muscoloskeletal symptoms induced by aromatase inhibitors: new therapeutic approach (C.L. Loprinzi) 10.00 Low-fat diet: is it really a predictor for the best outcome? (R.T. Chlebowski) 10.20 Physical exercise and breast cancer: risk correlation to subtype and therapeutic effect (D.C. McKenzie)
Presenting: P. Pronzato10.40 Lecture Adjuvant therapy in HER2 positive early breast cancer: for whom? How long? With what? (P. Conte)
11.00 Coffee Break
8TH SESSION
EVOLVING MOLECULESChairmen: G. Ferretti, V. Guarneri
11.10 Etirinotecal pegol: in which position in the future clinical choice? (C.J. Twelves) 11.30 Trop-2: potential target for antibody-drug conjugates (A. Bardia)
9TH SESSION
HORMONAL THERAPY AND NOVEL DISCOVERIES IN DRUG RESISTANCESChairmen: A. Fabi, V. Lorusso
11.50 Lecture Mechanism and clinical results in ER positive patients (A. Di Leo)12.10 New selective estrogen receptor antagonist (R.S. Finn)12.30 Lecture Clinical utility of multigene assays and outcome of disease (M. De Laurentiis)
10TH SESSION
AGE AND BREAST CANCERChairmen: A. Gennari, U. Tirelli
12.50 Evaluation and treatment of older patients (in early stage) (L.M. Repetto)13.10 The treatment of Metastatic disease in elderly patients, light and shadow (C. Fontanella)
13.30 Discussion and Conclusions
14.00 Lunch